Microdosing shrooms means taking a very small amount of psilocybin mushrooms, typically between 0.1 and 0.5 grams of dried material, on a repeating schedule. The dose is deliberately “sub-perceptual,” meaning it shouldn’t produce any hallucinations, visual distortions, or the feeling of being “high.” People who microdose report doing it to improve mood, creativity, and focus, though the scientific evidence is still catching up to the hype.
How Small Is a Microdose?
A full psychedelic dose of dried psilocybin mushrooms is generally 2 to 5 grams. A microdose is roughly one-tenth of that, landing in the range of 0.1 to 0.5 grams. At the upper end of that range (0.5 grams), a double-blind study published in Translational Psychiatry estimated the actual psilocybin content at approximately 0.9 milligrams. That’s a tiny amount of the active compound, but psilocybin is potent, and even small quantities interact with the brain’s serotonin system.
The potency of any given mushroom varies considerably depending on species, growing conditions, and which part of the mushroom you’re consuming. Two capsules made from different batches could contain meaningfully different amounts of psilocybin even if they weigh the same. This inconsistency is one of the practical challenges of microdosing outside a controlled setting.
What Psilocybin Does in the Brain
Once ingested, psilocybin is converted into psilocin, which binds to serotonin receptors, particularly a type called 5-HT2A. Activating these receptors triggers signaling cascades that promote neuroplasticity, the brain’s ability to form and strengthen new synaptic connections. At full doses, this process is dramatic enough to reshape patterns of brain activity for weeks or months. At microdose levels, the changes are subtler and harder to measure.
Research from Molecular Psychiatry has shown that psilocybin-driven neuroplasticity in the brain’s outer cortex was long assumed to require 5-HT2A receptors on the receiving neuron. Newer findings complicate that picture: neurons lacking those receptors can still undergo lasting synaptic strengthening, as long as the neurons sending signals to them have 5-HT2A receptors on their axons. In plain terms, psilocybin’s rewiring effects may be more widespread in the brain than scientists originally thought.
There’s also early evidence that sub-hallucinogenic doses reduce activity in the default mode network, a collection of brain regions active during mind-wandering and self-referential thinking. Overactivity in this network is associated with rumination and depression. One placebo-controlled EEG study using low doses of a related psychedelic (LSD) found reduced brain oscillatory power across all frequency bands, with higher microdoses producing larger reductions. No clinical trials have yet confirmed this effect specifically for psilocybin microdoses, though.
What People Report Feeling
The most common reasons people give for microdosing are improved mood, enhanced creativity, and sharper focus. A review of research on psychedelic doses found that while full doses tended to impair cognitive performance during the acute experience, microdoses showed a trend toward creative enhancement, particularly on tasks measuring divergent thinking (generating multiple solutions to an open-ended problem). Attention and vigilance tasks also showed some positive signals, though results were inconsistent across studies.
The challenge is separating real pharmacological effects from expectation. When people believe they’re taking something that will boost their creativity or lift their mood, they often report exactly that, even on placebo. Controlled studies have struggled to find large, consistent differences between microdose and placebo groups. Many of the most enthusiastic reports come from unblinded surveys and online communities, where the placebo effect and self-selection bias are strongest.
Common Microdosing Schedules
Two protocols dominate the microdosing world. The Fadiman protocol, named after psychologist James Fadiman, involves taking a microdose every fourth day: one day on, three days off. A typical cycle runs for several weeks, followed by a reset period of a week or more before starting again.
The Stamets stack, associated with mycologist Paul Stamets, combines a psilocybin microdose with lion’s mane mushroom (a non-psychoactive species studied for its nerve-growth properties) and niacin (vitamin B3). Stamets has suggested this combination may offer synergistic benefits for neurogenesis, though this specific stack hasn’t been tested in clinical trials.
Many people who microdose eventually adjust their schedule based on personal preference, dosing only when they feel they want a boost rather than following a rigid calendar. The built-in off days aren’t arbitrary, though. They exist for a biological reason.
Why Off Days Matter: Tolerance
Psilocybin tolerance builds quickly. After even a single dose, the brain begins a compensatory process: serotonin 2A receptors are pulled from the cell surface and their density in the cortex drops. This is called receptor downregulation. The result is that taking the same dose the next day produces a weaker effect, and taking it daily would likely lead to diminishing returns within days.
At the molecular level, the receptor gets flagged by proteins called arrestins after activation, which leads to its removal from the cell membrane. The brain needs time to replenish its receptor population before the next dose will work as intended. Spacing doses at least two to three days apart is the standard recommendation in microdosing communities, and the pharmacology supports that logic.
Side Effects and Risks
Microdosing is not side-effect-free. The National Center for Complementary and Integrative Health lists insomnia, increased anxiety, worsened depression, low energy, headaches, gastrointestinal discomfort, temperature regulation issues, poor focus, and impaired social functioning among reported negative effects. Some of these, particularly increased anxiety and disrupted sleep, are common enough that they show up repeatedly in survey-based studies.
A longer-term concern involves the heart. Psilocybin (and its active form, psilocin) binds with high affinity to 5-HT2B receptors, a receptor type that, when chronically activated, is linked to heart valve disease. This is the same mechanism that caused the weight-loss drug fenfluramine to be pulled from the market. In mice, a study published by the American Chemical Society found that chronic low-dose LSD (which shares similar receptor affinity) did not produce detectable heart valve or ventricular changes, even though 5-HT2B activation levels were substantial. The activation was short-lived compared to known cardiotoxins. These results are somewhat reassuring but come from animal models, and long-term human safety data for repeated psilocybin microdosing simply doesn’t exist yet.
Legal Status
Psilocybin remains a Schedule I controlled substance under U.S. federal law, meaning it’s classified as having no accepted medical use and high abuse potential. State-level changes are creating a patchwork of exceptions. Oregon established a regulated psilocybin therapy program in 2023. Colorado decriminalized personal cultivation, possession, and consumption of psilocybin mushrooms for adults 21 and older in 2022, and is set to offer regulated psychedelic therapy through healing centers in 2025. In Utah, a 2024 law created a pilot program allowing two health care systems to offer psilocybin treatments.
Several cities, including Denver, Oakland, Santa Cruz, and Washington D.C., have passed local decriminalization measures. Decriminalization generally means law enforcement treats possession as a low priority rather than making it fully legal. In most of the country, buying, possessing, or growing psilocybin mushrooms remains illegal regardless of the dose or your intentions.